Neoadjuvant terapi (Tx) for Merkelcellekarcinom med PD-1-hæmmeren Cemiplimab (NeoMatryx)
Neoadjuvant terapi (Tx) for Merkelcellekarcinom med PD-1-hæmmeren Cemiplimab - En randomiseret, dobbeltblindet, placebo-kontrolleret, ikke-komparativ fase II-studie
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Michelle Tez
- E-mail: tez.michelle@ikf-khnw.de
Undersøgelse Kontakt Backup
- Navn: Ralf Gutzmer, Prof. Dr. med.
- E-mail: Ralf.Gutzmer@Muehlenkreiskliniken.de
Studiesteder
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Tyskland, 69120
- Rekruttering
- Nationales Centrum für Tumorerkrankungen
-
Kontakt:
- Jessica Hassel, Prof. Dr.
-
Mannheim, Baden-Wurttemberg, Tyskland, 68161
- Rekruttering
- Universitätsklinikum Mannheim
-
Kontakt:
- Jochen Utikal, Prof. Dr.
-
Tübingen, Baden-Wurttemberg, Tyskland, 72076
- Rekruttering
- Universitätsklinikum Tübingen
-
Kontakt:
- Ulrike Leiter-Stöppke, Prof. Dr.
-
-
Bavaria
-
Regensburg, Bavaria, Tyskland, 93053
- Rekruttering
- Universitätsklinikum Regensburg
-
Kontakt:
- Sebastian Haferkamp, Prof. Dr.
-
Würzburg, Bavaria, Tyskland, 97080
- Rekruttering
- Universitätsklinikum Würzburg
-
Kontakt:
- Anja Gieserich, Dr.
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 20246
- Rekruttering
- Universitätsklinikum Hamburg-Eppendorf
-
Kontakt:
- Christoffer Gebhardt, Prof. Dr.
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60590
- Rekruttering
- Universitätsklinikum Frankfurt
-
Kontakt:
- Bastian Schilling, Prof. Dr.
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Tyskland, 33647
- Rekruttering
- Klinikum Bielefeld
-
Kontakt:
- Selma Ugurel, Prof. Dr.
-
Essen, North Rhine-Westphalia, Tyskland, 45147
- Rekruttering
- Universitätsklinikum Essen
-
Kontakt:
- Dirk Schadendorf, Prof. Dr.
-
Minden, North Rhine-Westphalia, Tyskland, 32429
- Ikke rekrutterer endnu
- Johannes Wesling Klinikum Minden
-
Kontakt:
- Ralf Gutzmer, Prof. Dr.
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Tyskland, 55131
- Rekruttering
- Universitätsmedizin Mainz
-
Kontakt:
- Stefan Grabbe, Prof. Dr.
-
-
Thuringia
-
Erfurt, Thuringia, Tyskland, 99089
- Rekruttering
- Helios Klinikum Erfurt
-
Kontakt:
- Rudolph Herbst, Prof. Dr.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria
-
Patient has signed informed written consent.
-
Patients is 18 years and older at time of signing of written informed consent
-
Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.
-
Patient has ECOG performance status 0-2.
-
Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.
- Absolute number of neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
- AST (SGOT) and ALT (SGPT) ≤ 3x ULN
- AP ≤ 2.5x ULN
- Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
-
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
-
Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
-
Patient has prior sentinel lymph node removal for the current MCC.
-
Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)
-
Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
-
Patient had prior organ transplantation including allogenic stem-cell transplantation.
-
Patient receives immunosuppressive concomitant medication, EXCEPT for the following:
i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).
ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
-
Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has active autoimmune or inflammatory disorders.
-
Patient has history of interstitial lung disease.
-
Patient has active infection requiring systemic therapy.
-
Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.
NOTE: Patients are eligible if:
- Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
- Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
- Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
-
Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
-
Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
-
Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
-
Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
-
Patient is legally incapacitated or has limited legal capacity
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm A (Cemiplimab)
2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy |
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Andre navne:
|
|
Placebo komparator: Arm B (placebo)
2 cycles of placebo followed by sentinel lymph node biopsy |
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Nodal micrometastases-free rate
Tidsramme: up to 36 months
|
rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
up to 36 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrence-free survival
Tidsramme: up to 66 months
|
time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death |
up to 66 months
|
|
Time to recurrence
Tidsramme: up to 66 months
|
defined as time from randomization until date of first MCC recurrence |
up to 66 months
|
|
Overall survival
Tidsramme: up to 66 months
|
time from randomization until date of death from any cause |
up to 66 months
|
|
Quality of life using FCRI-SF questionnaire
Tidsramme: up to 66 months
|
Quality of life determined using the FCRI-SF questionnaire |
up to 66 months
|
|
Safety (AEs and SAEs)
Tidsramme: up to 66 months
|
incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
up to 66 months
|
|
Disease specific survival
Tidsramme: up to 66 months
|
time from randomization until date of MCC-related death |
up to 66 months
|
|
Quality of life using the mFACT-M questionnaire
Tidsramme: up to 66 months
|
Quality of life determined using the mFACT-M questionnaire |
up to 66 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Tidsramme: up to 66 months
|
Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS |
up to 66 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
- Ledende efterforsker: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
- Ledende efterforsker: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Infektioner
- Virussygdomme
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- DNA-virusinfektioner
- Hudsygdomme
- Karcinom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neuroendokrine tumorer
- Tumorvirusinfektioner
- Polyomavirus infektioner
- Karcinom, neuroendokrin
- Hud- og bindevævssygdomme
- Neoplasmer i huden
- Karcinom, Merkel Cell
- cemiplimab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NeoMatryx
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .